Program
povorcitinib
Also written as “Povorcitinib” and “INCB054707”.
Its studies are mostly in Hidradenitis Suppurativa · Prurigo · Vitiligo · Renal Insufficiency · Asthma, led by Incyte.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Incyte | 238 open or running | phase 3since Nov 10, 2022 | May 24, 2018 | Nov 20, 2026phase 2 · NCT05851443 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 5 studies since May 24, 2018.
- Sep 27, 2021Phase 1 study in Healthy ParticipantsNCT05068466 · 30 enrolled · Japan
- Nov 10, 20222 phase 3 studies in Hidradenitis SuppurativaNCT05620836, NCT05620823
- Nov 11, 20222 phase 1 studies in Renal InsufficiencyNCT05624723, NCT05624710
- Apr 24, 2023Phase 2 study in AsthmaNCT05851443 · 247 enrolled · United States, Argentina, Canada and more
- Jun 26, 2023Phase 2 study in UrticariaNCT05936567 · 136 enrolled · United States, Germany, Poland
- Oct 27, 20232 phase 3 studies in NonSegmental VitiligoNCT06113471, NCT06113445
- Jan 9, 2024Phase 3 study in Hidradenitis SuppurativaNCT06212999 · 617 enrolled · United States, Australia, Austria and more
- Apr 3, 2024Phase 1 study in Healthy ParticipantsNCT06380205 · 24 enrolled · United States
- May 29, 2024Phase 1 study in Healthy ParticipantsNCT06441318 · 128 enrolled · United States
- Jul 8, 2024Phase 1 study in Healthy ParticipantsNCT06505265 · 18 enrolled · United States
- Jul 18, 20242 phase 3 studies in Prurigo NodularisNCT06516965, NCT06516952
- Feb 26, 2025Phase 3 study in Hidradenitis SuppurativaNCT06855498 · 600 planned · United States, Argentina, Australia and more
- Oct 7, 2025Phase 2 study in Hidradenitis SuppurativaNCT07213973 · 40 planned · United States, Canada
- May 8, 2026Phase 1 study in Healthy ParticipantsNCT07588139 · 24 enrolled · United States
Ahead
- Nov 20, 2026Primary completion: phase 2 study in AsthmaNCT05851443
- Dec 26, 2026Primary completion: phase 3 study in Hidradenitis SuppurativaNCT06212999
- Feb 28, 2028Primary completion: phase 3 study in Hidradenitis SuppurativaNCT06855498
- Mar 25, 2028Primary completion: phase 2 study in Hidradenitis SuppurativaNCT07213973
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 23 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07588139Healthy Participants · United States | 1 | Completed | Sep 8, 2026 | 24 |
| NCT07213973Hidradenitis Suppurativa · United States, Canada | 2 | Recruiting | Mar 25, 2028 | 40 |
| NCT06855498Hidradenitis Suppurativa · United States, Argentina, Australia and more | 3 | Recruiting | Feb 28, 2028 | 600 |
| NCT06516965Prurigo Nodularis · United States, Australia, Belgium and more | 3 | Active, not recruiting | Sep 28, 2026 | 346 |
| NCT06516952Prurigo Nodularis · United States, Argentina, Austria and more | 3 | Active, not recruiting | Oct 19, 2026 | 349 |
| NCT06505265Healthy Participants · United States | 1 | Completed | Sep 18, 2024 | 18 |
| NCT06441318Healthy Participants · United States | 1 | Completed | Sep 10, 2024 | 128 |
| NCT06380205Healthy Participants · United States | 1 | Completed | Jun 7, 2024 | 24 |
| NCT06212999Hidradenitis Suppurativa · United States, Australia, Austria and more | 3 | Active, not recruiting | Dec 26, 2026 | 617 |
| NCT06113471NonSegmental Vitiligo · United States, Bulgaria, Canada and more | 3 | Active, not recruiting | Mar 17, 2026 | 450 |
| NCT06113445NonSegmental Vitiligo · United States, Belgium, Canada and more | 3 | Active, not recruiting | Feb 24, 2026 | 467 |
| NCT05936567Urticaria · United States, Germany, Poland | 2 | Completed | Feb 28, 2025 | 136 |
| NCT05851443Asthma · United States, Argentina, Canada and more | 2 | Active, not recruiting | Nov 20, 2026 | 247 |
| NCT05624723Renal Insufficiency · United States, Germany | 1 | Completed | Feb 7, 2024 | 43 |
| NCT05624710Renal Insufficiency · United States, Germany | 1 | Completed | Jun 30, 2023 | 25 |
| NCT05620836Hidradenitis Suppurativa · United States, Australia, Bulgaria and more | 3 | Completed | Jan 7, 2025 | 619 |
| NCT05620823Hidradenitis Suppurativa · United States, Austria, Belgium and more | 3 | Completed | Feb 3, 2025 | 608 |
| NCT05068466Healthy Participants · Japan | 1 | Completed | Jan 25, 2022 | 30 |
| NCT05061693Prurigo Nodularis · United States, Canada, Germany and more | 2 | Completed | Aug 11, 2023 | 146 |
| NCT04818346NonSegmental Vitiligo · United States, Canada | 2 | Completed | May 24, 2022 | 171 |
| NCT04476043Hidradenitis Suppurativa · United States, Canada, France and more | 2 | Completed | Dec 15, 2021 | 209 |
| NCT03607487Hidradenitis Suppurativa · Canada, Denmark, Germany | 2 | Completed | Aug 13, 2019 | 35 |
| NCT03569371Hidradenitis Suppurativa · United States | 2 | Completed | Apr 22, 2019 | 10 |
How it is read
Names in the registry
- “Povorcitinib”, 13 entries
- “INCB054707”, 8 entries
- “povorcitinib”, 2 entries
Conditions, from the studies’ own filings
- Hidradenitis Suppurativa, 8 studies
- Prurigo, 3 studies
- Vitiligo, 3 studies
- Renal Insufficiency, 2 studies
- Asthma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.